NK

NantKwest
NASDAQ

Real-time Quotes | Nasdaq Last Sale

26.58
-1.78
-6.28%
Pre Market: 25.36 -1.22 -4.59% 07:32 03/04 EST
OPEN
28.08
PREV CLOSE
28.36
HIGH
28.66
LOW
26.13
VOLUME
20
TURNOVER
--
52 WEEK HIGH
45.42
52 WEEK LOW
2.520
MARKET CAP
2.90B
P/E (TTM)
-35.4353
1D
5D
1M
3M
1Y
5Y
NantKwest's Charts Are Extended When Compared to the Popular Moving Averages
Let's stand aside for now and see how things unfold....NK
TheStreet.com · 2d ago
Cramer Advises Viewers On First Solar, Madison Square Garden Sports And More
Jim Cramer spoke on CNBC's "Mad Money Lightning Round" about Nantkwest Inc (NASDAQ: NK). He said it is a great immunotherapy company.
Benzinga · 3d ago
Cramer's lightning round: Madison Square Garden Sports is a 'good idea'
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
CNBC.com · 5d ago
Press Release: All Three Independent Proxy -2-
Dow Jones · 02/25 00:26
BRIEF-ImmunityBio Appoints John Brennan And Wesley Clark To Board Of Directors
reuters.com · 02/24 14:16
ImmunityBio Appoints John Brennan and Wesley Clark to Board of Directors
ImmunityBio, Inc., a privately-held immunotherapy company, today announced the appointment of John Brennan, former Central Intelligence Agency Director, and Wesley Clark, retired U.S. Army General, to the company's board of directors, effective immediately...
BusinessWire · 02/24 14:00
DJ NantKwest Down Over 25%, On Pace for Largest Percent Decrease Since January 2020 -- Data Talk
Dow Jones · 02/23 20:23
INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - CTB, PBCT, HMSY, NK, SPWH
, /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
PR Newswire - PRF · 02/23 13:01
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NK. Analyze the recent business situations of NantKwest through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NK stock price target is 18.00 with a high estimate of 18.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 163
Institutional Holdings: 12.35M
% Owned: 11.33%
Shares Outstanding: 109.00M
TypeInstitutionsShares
Increased
32
2.61M
New
51
-872.07K
Decreased
23
279.15K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.96%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chairman/Executive Director
Patrick Soon-Shiong
President/Chief Administrative Officer/Director
Barry Simon
Chief Executive Officer
Richard Adcock
Chief Financial Officer
Sonja Nelson
Lead Director/Independent Director
Frederick Driscoll
Director
Cheryl Cohen
Independent Director
Michael Blaszyk
Independent Director
John Thomas
No Data
About NK
NantKwest, Inc. is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Its immuno-oncology NK platform has multiple modes to induce cell death against the tumor or infected cell by direct killing by binding to stress ligands expressed by the diseased cell with the release of toxic granules directly into the tumor cell; antibody mediated killing by binding to antibodies administered in combination and enhancing the cancer killing effect of the administered antibody, enabling targeted cell killing through antibody dependent cellular cytotoxicity (ADCC), and target activated killing by binding to known or newly discovered tumor-specific antigens expressed on the surface of tumor cells and inducing cell death by the release of toxic granules directly into the tumor cell and by the release of cytokines and chemokines.

Webull offers kinds of Nantkwest Inc stock information, including NASDAQ:NK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NK stock methods without spending real money on the virtual paper trading platform.